The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
Sevil E. Bavbek
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Sanofi
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Sanofi
Zafar Malik
Honoraria - advisory board; Sponsorship to attend ASCO-GU meeting
Giuseppe Di Lorenzo
No relevant relationships to disclose
Hans-Jorg Scholz
No relevant relationships to disclose
Inge M van Oort
No relevant relationships to disclose
Siobhan Ng
Consultant or Advisory Role - Australian cabazitaxel advisory board (U)
Other Remuneration - Sponsorship to attend ASCO meeting
Mustafa Ozguroglu
Consultant or Advisory Role - ProStrtic
Honoraria - Advisory board x 2
Winald R. Gerritsen
Consultant or Advisory Role - Sanofi
Stefan Mueller
No relevant relationships to disclose
Timo Marttila
Consultant or Advisory Role - Sanofi
Luis Antón-Aparicio
No relevant relationships to disclose
Luis M. Anton-Aparicio
Disclosure not yet available
Peter Albers
Honoraria - Sanofi
Juergen Gschwend
No relevant relationships to disclose
Samira Bensfia
Employment or Leadership Position - Sanofi
Evelyne B Ecstein-Fraïssé
Employment or Leadership Position - Sanofi
Sergio Bracarda
Consultant or Advisory Role - Johnson & Johnson; Sanofi
Honoraria - Sanofi
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Honoraria - Amgen; Astellas Pharma; Bayer; GlaxoSmithKline; Ipsen; Janssen-Cilag; Pfizer